about
Walkrounds in practice: corrupting or enhancing a quality improvement intervention? A qualitative studyCulture and behaviour in the English National Health Service: overview of lessons from a large multimethod study.How collaborative are quality improvement collaboratives: a qualitative study in stroke care.Running a hospital patient safety campaign: a qualitative study.Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland.A pill too hard to swallow: how the NHS is limiting access to high priced drugs.The politics of health technology assessment in PolandDisclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohortsExposing drug industry funding of UK patient organisations.Wales approves new hepatitis C drug while England deliberatesThe whistleblowing drama behind Astellas's suspension from the ABPIPatterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016How not to waste a crisis: a qualitative study of problem definition and its consequences in three hospitalsAlternative access schemes for pharmaceuticals in Europe: Towards an emerging typologyEvaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UKAnalysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015Shedding light on the HTA consultancy market: Insights from Poland
P50
Q37021021-1461BDF2-F23B-4280-AB9A-ABB5059C617AQ37552998-74CC987D-47C2-4C3D-BA0D-386DB3A8047EQ37698344-8931E169-FD57-4BF4-9961-8A27C3441EB6Q37705425-C2F94873-3545-4172-9223-F8E7059370FEQ37912288-ADABBC35-02FA-4DA5-9A5B-61D55A7C8409Q50209391-AA6E30B4-8E53-4E76-B849-918AA5DF8FA2Q50600566-440179F8-515E-47FF-80AD-C3C123525F57Q57763644-96E10654-5EEA-4E55-B817-EDCC98E03185Q57806288-8C241F56-03AA-43D2-BCCC-2A2178F6BDB0Q64970256-B50E464B-AB9D-4B95-9D79-CA35F33841B8Q88891230-89087BA2-39C0-4CBE-A40F-A0871070352AQ91562928-D3CE55D4-2E0E-4405-8B4C-3961F501EA12Q91662281-2D7EFF96-90DE-4E1A-BE47-2260C77B623EQ92055274-220E2A77-90F8-4589-804F-2F9DB426FD79Q92303253-8FCB2B3F-8567-4367-9B80-68F72296E149Q92911674-3F8A7BFE-1D36-4486-8977-660B637BF816Q92934895-F7702EA9-DCB5-4DA3-91C3-77E442846BE5Q92991224-9873BA45-AEC9-4FA2-AAC7-14F0D3123EEC
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Piotr Ozierański
@en
Piotr Ozierański
@nl
type
label
Piotr Ozierański
@en
Piotr Ozierański
@nl
prefLabel
Piotr Ozierański
@en
Piotr Ozierański
@nl
P31
P496
0000-0002-2023-3288